The present invention relates to a novel class of chromene-2-carboxamide compounds inhibitors of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and their use as anti-infective agents in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
[EN] SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] PYRIMIDINE SUBSTITUÉE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
申请人:HOFFMANN LA ROCHE
公开号:WO2021063852A1
公开(公告)日:2021-04-08
The present invention provides novel compounds having the general formula: wherein R1 to R4, L1, L2 and X are as described herein, compositions including the compounds and methods of using the compounds.
SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
申请人:Hoffmann-La Roche Inc.
公开号:US20220396567A1
公开(公告)日:2022-12-15
The present invention provides novel compounds having the general formula: wherein
R1
to R
4
, L
1
, L
2
and X are as described herein, compositions including the compounds and methods of using the compounds.
Compounds for inhibiting NLRP3 and uses thereof
申请人:Ventus Therapeutics U.S., Inc.
公开号:US11319319B1
公开(公告)日:2022-05-03
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):